On April 28, 2026, the 2025 Forbes China ESG Image Enterprise Figures Summit and Awards Ceremony concluded in a landmark gathering that brought together over 500 global dignitaries, diplomatic envoys, and industry leaders from across the world.
Among those honored was Dr. Hu Junyuan, founder and chairman of Beike Biotechnology, who received the distinguished title of “2025 Forbes China ESG Impact Enterprise Figure”, a recognition of his decades-long commitment to advancing life sciences through innovation, integrity, and a vision for sustainable healthcare.
A Recognition With Significant Weight
Forbes China’s ESG selection process is one of the most rigorous and respected in the country. Organized by the official Chinese affiliate of Forbes Media, the selection evaluates candidates across five dimensions: innovative capability, environmental contribution, social impact, corporate governance, and future potential.
Past honorees and figures highlighted within this selection system include Xiaomi founder Lei Jun, DeepSeek founder Liang Wenfeng, and Yushu Technology founder Wang Xingxing, names that represent the leading edge of China’s technological and industrial transformation.
Dr. Hu’s inclusion in this cohort signals not only personal achievement but recognition of Beike Biotechnology’s position as a globally competitive force in ESG-aligned life sciences.
Two Decades of Mission-Driven Innovation
Founded in 2005 with the mission of “relentless efforts to improve human health,” Beike Biotechnology has spent over 21 years advancing the clinical translation of biotherapeutic technologies. The company has built a comprehensive R&D platform spanning cell technology, organoids, and metabolomics, consistently pushing the frontier of what’s possible in regenerative medicine.
In recent years, Beike has achieved breakthrough results in cell-based research and new drug development, reinforcing its role as a pioneer in the global biotech landscape.
ESG as a Core Business Philosophy
This award affirms what has always been central to Beike’s identity: that scientific excellence and responsible business practice are not competing priorities – they are the same.
Dr. Hu’s recognition as a Forbes China ESG benchmark figure reflects Beike’s long-term commitment to protecting human life through technology, operating with transparency and governance, and expanding access to cutting-edge therapies to a broader population worldwide.
As Beike Biotechnology looks ahead, this honor serves as both validation and motivation to continue driving sustainable development through innovation and to be a trusted, credible force in global life and health.